Johnson & Johnson seeks FDA approval for SPRAVATO in treatment-resistant depression
Johnson & Johnson (NYSE: JNJ) is seeking U.S. Food and Drug Administration (FDA) approval for SPRAVATO (esketamine) as a standalone treatment for adults with treatment-resistant ... Read More
Huge relief for GERD patients: Phathom Pharmaceuticals wins FDA nod for VOQUEZNA
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a pioneering biopharmaceutical company, has received U.S. Food and Drug Administration (FDA) approval for VOQUEZNA 10 mg tablets, designed to ... Read More
FDA approves Arcutis Biotherapeutics’ ZORYVE for pediatric and adult atopic dermatitis
In a significant development for the treatment of atopic dermatitis (AD), Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the U.S. Food and Drug Administration (FDA) approval ... Read More
Genentech announces reintroduction of Susvimo for Wet AMD treatment in US
Genentech, a key member of the Roche Group, has officially announced the reintroduction of Susvimo (ranibizumab injection) 100 mg/mL, a cutting-edge treatment for wet, or ... Read More
FDA approves Roche’s Vabysmo prefilled syringe for eye diseases, expanding treatment options for millions
Roche (SIX: RO, ROG; OTCQX: RHHBY), a global leader in pharmaceuticals and diagnostics, announced a significant advancement in eye care with the U.S. Food and ... Read More
Johnson & Johnson’s TB drug SIRTURO receives full approval from FDA and EC
In a significant development for the treatment of drug-resistant tuberculosis (TB), Johnson & Johnson has announced that SIRTURO (bedaquiline) has received full approval from the ... Read More
FDA approves Genentech’s Vabysmo prefilled syringe for eye diseases
In a significant advancement in the treatment of eye diseases, the U.S. Food and Drug Administration (FDA) has approved Genentech's Vabysmo (faricimab-svoa) 6.0 mg single-dose ... Read More
FDA approves Eli Lilly’s Kisunla for Alzheimer’s treatment
The U.S. Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt), an Alzheimer's treatment developed by Eli Lilly and Company (NYSE: LLY). This treatment, specifically ... Read More
Signet Therapeutics gets FDA IND approval for sigx1094 in diffuse gastric cancer
Signet Therapeutics, a pioneering biotech company, has achieved a significant milestone with the US Food and Drug Administration (FDA)'s Investigational New Drug (IND) approval of ... Read More
FDA approves Halozyme’s VYVGART Hytrulo for CIDP treatment
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approval of VYVGART Hytrulo (efgartigimod alfa and ... Read More